Frequent Emergence of Resistance Mutations Following Complex Intra-Host Genomic Dynamics in SARS-CoV-2 Patients Receiving Sotrovimab

• Published in: Antimicrobial agents and chemotherapy Vol. 67; no. 7; p. e0026623
• Main Authors: Palomino-Cabrera, Rosalía, Tejerina, Francisco, Molero-Salinas, Andrea, Ferris, María, Veintimilla, Cristina, Catalán, Pilar, Rodríguez Macias, Gabriela, Alonso, Roberto, Muñoz, Patricia, García de Viedma, Darío, Pérez-Lago, Laura
• Format: Journal Article
• Language: English
• Published: United States American Society for Microbiology 18.07.2023
• Subjects: Antibodies, Neutralizing; Antiviral Agents; Clinical Microbiology; COVID-19; Genomics; Humans; Mutation; Retrospective Studies; SARS-CoV-2 - genetics; COVID-19
• ISSN: 0066-4804; 1098-6596
• DOI: 10.1128/aac.00266-23

The emergence of the Omicron variant of SARS-CoV-2 represented a challenge to the treatment of COVID-19 using monoclonal antibodies. Only Sotrovimab maintained partial activity, allowing it to be used in high-risk patients infected with the Omicron variant. However, reports of resistance mutations to Sotrovimab demand efforts to better understand the intra-patient emergence of Sotrovimab resistance. A retrospective genomic analysis was conducted on respiratory samples from immunocompromised patients infected with SARS-CoV-2 who received Sotrovimab at our hospital between December 2021 and August 2022. The study involved 95 sequential specimens from 22 patients (1 to 12 samples/patient; 3 to 107 days post-infusion; threshold cycle [ ] ≤ 32). Resistance mutations (in P337, E340, K356, and R346) were detected in 68% of cases; the shortest time to detection of a resistance mutation was 5 days after Sotrovimab infusion. The dynamics of resistance acquisition were highly complex, with up to 11 distinct amino acid changes in specimens from the same patient. In two patients, the mutation distribution was compartmentalized in respiratory samples from different sources. This is the first study to examine the acquisition of Sotrovimab resistance in the BA.5 lineage, enabling us to determine the lack of genomic or clinical differences between Sotrovimab resistance in BA.5 relative to that in BA.1/2. Across all Omicron lineages, the acquisition of resistance delayed SARS-CoV-2 clearance (40.67 versus 19.5 days). Close, real-time genomic surveillance of patients receiving Sotrovimab should be mandatory to facilitate early therapeutic interventions.